Skip to main content

All Resources

Filter

All ResourcesNews

Fda approves wezlana as an interchangeable biosimilar to stelara for Multiple Inflammatory Diseases

The US Food and Drug Administration (FDA) has approved Wezlana (ustekinumab-auub) as…
Read More
All ResourcesEvents

Navigating the Future of the Healthcare Industry: Insights into CPhI Europe

The healthcare sector has been brought to the forefront of global innovation…
Read More
All ResourcesLatest Approval

FDA approves Sandoz Tyruko for the treatment of multiple sclerosis

Tyruko (natalizumab-site), a natalizumab biosimilar, has been authorized by the FDA as…
Read More
Horizon Therapeutics Claims Top Spot in Rare disease
All ResourcesNews

Horizon Therapeutics takes the rare disease reputation crown

Another wreath has been added to Horizon Therapeutics' pre-takeover victory lap. Months…
Read More
Treatment for CHAPLE Disease
All ResourcesLatest Approval

FDA Approves Breakthrough Treatment for CHAPLE Disease

FDA has recently approved the first-ever treatment for pancreatitis, a protein-loss form…
Read More
Invimeds in Expopharm 2023
All ResourcesEvents

INVIMEDS HEALTH TO PRESENT INNOVATIONS AT EXPOPHARM 2023, DUSSELDORF

A prominent role player in the pharmaceutical and healthcare industry, InviMeds Health…
Read More
Invimeds at Arab Health 2023
All ResourcesEvents

A Successful Collaboration: InviMeds Health Shines at ARAB HEALTH 2023

InviMeds Health a leading healthcare company is proud to announce its successful…
Read More

Filter

All ResourcesEvents

Navigating the Future of the Healthcare Industry: Insights into CPhI Europe

The healthcare sector has been brought to the forefront of global innovation…
Read More
Invimeds in Expopharm 2023
All ResourcesEvents

INVIMEDS HEALTH TO PRESENT INNOVATIONS AT EXPOPHARM 2023, DUSSELDORF

A prominent role player in the pharmaceutical and healthcare industry, InviMeds Health…
Read More
Invimeds at Arab Health 2023
All ResourcesEvents

A Successful Collaboration: InviMeds Health Shines at ARAB HEALTH 2023

InviMeds Health a leading healthcare company is proud to announce its successful…
Read More

Filter

All ResourcesLatest Approval

FDA approves Sandoz Tyruko for the treatment of multiple sclerosis

Tyruko (natalizumab-site), a natalizumab biosimilar, has been authorized by the FDA as…
Read More
Treatment for CHAPLE Disease
All ResourcesLatest Approval

FDA Approves Breakthrough Treatment for CHAPLE Disease

FDA has recently approved the first-ever treatment for pancreatitis, a protein-loss form…
Read More

Filter

All ResourcesNews

Fda approves wezlana as an interchangeable biosimilar to stelara for Multiple Inflammatory Diseases

The US Food and Drug Administration (FDA) has approved Wezlana (ustekinumab-auub) as…
Read More
Horizon Therapeutics Claims Top Spot in Rare disease
All ResourcesNews

Horizon Therapeutics takes the rare disease reputation crown

Another wreath has been added to Horizon Therapeutics' pre-takeover victory lap. Months…
Read More

Stay In Touch!

Subscribe to our newsletter to receive news and updates.